Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Multiple Sclerosis News

News
Ponesimod More Effective than Teriflunomide at Treating Relapsing Multiple Sclerosis
04/13/2021
The first phase 3 trial comparing ponesimod to teriflunomide found ponesimod to be more effective at reducing the annualized relapse rate in multiple sclerosis (MS) patients.
The first phase 3 trial comparing ponesimod to teriflunomide found ponesimod to be more effective at reducing the annualized relapse rate in multiple sclerosis (MS) patients.
The first phase 3 trial...
04/13/2021
Neurology
News
FDA Approves Ponesimod for Adults With Relapsing Multiple Sclerosis
04/08/2021
The US Food and Drug Administration has recently approved ponesimod, an oral treatment, for adults with relapsing multiple sclerosis.
The US Food and Drug Administration has recently approved ponesimod, an oral treatment, for adults with relapsing multiple sclerosis.
The US Food and Drug...
04/08/2021
Neurology
News
Could Multiple Sclerosis Have Bidirectional Association With Depression?
02/25/2021
In a bidirectional Mendelian randomization study, researchers used recent genome-wide association study data to further examine the relationship between multiple sclerosis and depression.
In a bidirectional Mendelian randomization study, researchers used recent genome-wide association study data to further examine the relationship between multiple sclerosis and depression.
In a bidirectional Mendelian...
02/25/2021
Neurology

Advertisement

News
In RRMS, DMTs Appear to Be Efficacious Regardless of Age
02/18/2021
In a recent analysis of 26 trials that had examined 14 disease-modifying therapies (DMT) among patients with relapsing-remitting multiple sclerosis, researchers aimed to examine whether age impacted DMT efficacy.
In a recent analysis of 26 trials that had examined 14 disease-modifying therapies (DMT) among patients with relapsing-remitting multiple sclerosis, researchers aimed to examine whether age impacted DMT efficacy.
In a recent analysis of 26...
02/18/2021
Neurology
News
In MS, Relapse Associated with Worsened Cognitive Function
01/26/2021
A new study published in Multiple Sclerosis Journal replicated prior findings indicating that cognitive function declines during a relapse among patients with multiple sclerosis.
A new study published in Multiple Sclerosis Journal replicated prior findings indicating that cognitive function declines during a relapse among patients with multiple sclerosis.
A new study published in...
01/26/2021
Neurology
News
National Multiple Sclerosis Society Releases COVID-19 Vaccination Guidance
01/15/2021
The National Multiple Sclerosis Society has issued recommendations for the use of the COVID-19 vaccine among patients with multiple sclerosis.
The National Multiple Sclerosis Society has issued recommendations for the use of the COVID-19 vaccine among patients with multiple sclerosis.
The National Multiple Sclerosis...
01/15/2021
Neurology

Advertisement

News
Oligoclonal IgM Bands in Relapsing MS: A Potential Biomarker of Long-Term Disability?
01/13/2021
In a new study published in Multiple Sclerosis Journal, researchers investigated potential cerebrospinal fluid markers for long-term disability among patients with relapsing multiple sclerosis.
In a new study published in Multiple Sclerosis Journal, researchers investigated potential cerebrospinal fluid markers for long-term disability among patients with relapsing multiple sclerosis.
In a new study published in...
01/13/2021
Neurology
News
Early Intensive Treatment vs Escalation: Which is More Effective for RRMS?
09/14/2020
Because no consensus currently exists for when and how aggressively to treat relapsing-remitting multiple sclerosis (RRMS), researchers compared the effects of early intensive treatment vs moderate-efficacy treatment followed by escalation...
Because no consensus currently exists for when and how aggressively to treat relapsing-remitting multiple sclerosis (RRMS), researchers compared the effects of early intensive treatment vs moderate-efficacy treatment followed by escalation...
Because no consensus currently...
09/14/2020
Neurology
News
Rituximab for MS: New Safety, Efficacy Data Presented at MSVirtual2020
09/11/2020
Rituximab (RTX), an anti-CD20 monoclonal antibody, is commonly used as an off-label treatment for multiple sclerosis (MS). In a new study presented at MSVirtual2020, researchers compared the safety and efficacy of RTX at low and high doses...
Rituximab (RTX), an anti-CD20 monoclonal antibody, is commonly used as an off-label treatment for multiple sclerosis (MS). In a new study presented at MSVirtual2020, researchers compared the safety and efficacy of RTX at low and high doses...
Rituximab (RTX), an anti-CD20...
09/11/2020
Neurology

Advertisement

News
FDA Approves Cancer Drug to Treat Relapsing Multiple Sclerosis
08/21/2020
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
A drug that was first approved...
08/21/2020
Neurology

Advertisement

Advertisement

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use